Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
zanzalintinib + belzutifan
- Development stage
- Unknown
- Lead developer
- Exelixis
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**Zanzalintinib + belzutifan** is an investigational combination therapy being studied for the treatment of clear cell renal cell carcinoma (ccRCC). Zanzalintinib (also known as XL092) is a small molecule multi-targeted tyrosine kinase inhibitor (TKI) that inhibits various receptors involved in tumor growth and angiogenesis, notably VEGF receptors. Belzutifan is a small molecule inhibitor of hypoxia-inducible factor 2α (HIF-2α), disrupting hypoxic signaling pathways that drive cancer cell survival and proliferation. The combination is under evaluation for efficacy and safety in patients with ccRCC who have recurrent disease after prior anti‑PD‑(L)1 therapy, in investigational trials.
- Brand names
- Welireg
- Other names
- zanzalintinib and belzutifan
02
Targets
EPAS1 (Hypoxia-inducible factor 2-alpha)
Beyond the preview
Go deeper on zanzalintinib + belzutifan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on zanzalintinib + belzutifan.